Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Qlucore Receives European Funding That will Benefit Personalized Medicine

Published: Thursday, September 05, 2013
Last Updated: Thursday, September 05, 2013
Bookmark and Share
Hepatitis C patients to benefit from European funding awarded to Qlucore.

Qlucore has been awarded funding of €0.6 million over a three year period by the European Commission's 7th Framework Programme as part of a €6.0 million consortium project (Grant n° 601851) for the development of mathematical and statistical algorithms focusing on integrating data from multiple analytical platforms focusing on integrating genetic and proteomic data with clinical variables.

On receiving the award, Carl-Johan Ivarsson, CEO, Qlucore said, "Personalized medicine, and in particular Hepatitis C patients, will benefit from the project outcome. One of the primary objectives of the consortium is to provide predictive tests that will lead to improvements in the health of these patients, which will simultaneously reduce the costs of medical treatment."

The consortium, known as the PoC-HCV consortium, aims to develop integrated genetic and protein biomarker tests for use in treating and monitoring HCV patients, as well as in clinical research.

Data and algorithms will be tailored for analysis and treatment in a Point of Care environment for Hepatitis C. One of the outputs from the consortium will be a mobile application prototype where the algorithms are implemented.

Establishing a path for validation and implementation of point-of-care medical devices is a challenge, and the driving vision of the Consortium.

The consortium additionally consists of the coordinator Inserm (Institut Pasteur) (France), Inserm Transfert (France), Epistem (UK) and Biosurfit (Portugal).

With the primary objective to provide Point of Care diagnostic and predictive tests and reduce costs, the approach will capitalize on the consortium's combined expertise spanning leading edge miniaturized molecular testing, lab-on-a-chip systems and algorithm design.

These enabling technologies will permit the development and delivery of the first integrated genetic and protein biomarker tests, applied here to Hepatitis C disease for: (i) making the decision to treat; (ii) selection of therapy; (iii) response-guided monitoring; and (iv) clinical research practices.

Hepatatis-C is a global public health problem with over 150 million people infected worldwide, representing a 15 billion Euro/year market. It is particularly prevalent in under-developed countries and treatments can be very costly.

One vision is to allow the physicians to make better treatment decisions (selecting the correct drug) and hence lower the total cost of treatment. In countries with many infected patients and limited healthcare budget this will provide an enormous improvement in quality of life for this patient group.

The algorithms developed by Qlucore will be based on classification techniques. They will also be available in future versions of Qlucore Omics Explorer and hence enable researchers and physicians in other areas to benefit from the results.

Qlucore has recruited and increased its engineering capacity in order to fulfil its role in the PoC HCV consortium. This, combined with the recently announced grant to Qlucore from VINNOVA (Swedish Governmental Agency for Innovation Systems) is additional validation of the high value being placed on developments currently being undertaken by Qlucore.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Qlucore, Nebion Collaborate
Partnership aims to address complementary use cases.
Friday, February 07, 2014
Researchers Develop Animal Free Methods for Testing Chemical Compounds for Allergens
EU-funded research project developing in vitro (‘out of body’) test strategies to reduce or replace animal testing use gene expression analysis software.
Monday, April 08, 2013
Visualising Complex Data Results from 100,000 Cancer Patients
For decades, biomedical scientists have tried to develop a diagnostic tool for the early stages of cancer.
Wednesday, December 12, 2012
New Biomarkers Could Offer Vital Clues for Cancer Research
European funding for cancer research has led to some interesting results in recent years, says Carl-Johan Ivarsson, CEO at Qlucore.
Friday, May 04, 2012
Unlocking the Secrets of Complex Genetic Data
A new approach to data analysis is helping researchers at Cincinnati Children's Hospital Medical Center to unravel the mysteries of human disease, says Carl-Johan Ivarsson, President of Qlucore.
Monday, March 19, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Stem Cells Growing 3D Lung-in-a-Dish
Researchers have created 3D lung-like tissue from lung-derived stem cells. The tissue can be used to study lung diseases.
The Genetics of Blood Pressure
Researchers have identifed areas of the genome associated with blood-pressure including 17 previously unknown loci.
Mystery of Early Embryonic Development Solved
Breakthrough genomics technique can be used to map epigenetic marks across the genome using fewer cells and will benefit cancer research
Mouse Genes Guiding Precision Medicine
Research of the mouse genome has identified hundreds of essential-to-life genes from the 1751 genes studied.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Schizophrenia Drug Response Dictated by Genes
Study suggests schizophrenia drug may decrease negative symptoms for people with certain gene variant.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!